30 HUDSON STREET, JERSEY CITY, NJ
Appoints Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation
Reports Results for the Second Quarter
News
US Food and Drug Administration (FDA) Grants Interchangeability Designation to HADLIMA™ (adalimumab-bwwd) Injection
First Quarter 2025 Earnings
Annual Report to Security Holders
Appoints Ramona A. Sequeira to the Board of Directors
Fourth Quarter and Full Year 2024 Earnings
Q2
Q1
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
Certificate
Amended Direct Registration System
Direct Registration System
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Specialized Disclosure Report
Submission Upload
Correspondence